logo
  

AstraZeneca, Daiichi Sankyo: ENHERTU Demonstrated Durable Responses In Phase II Trial

AstraZeneca plc (AZN.L,AZN) and Daiichi Sankyo Co. Limited (DSKYF.PK) said Thursday that updated results from the positive DESTINY-Breast01 Phase II trial showed ENHERTU (fam-trastuzumab deruxtecan-nxki) continued to demonstrate impressive efficacy and durable responses in patients with HER2-positive metastatic breast cancer following two or more prior HER2-based regimens.

With a median duration of follow-up of 20.5 months, patients treated with ENHERTU achieved an objective response rate or ORR of 61.4 percent and a median duration of response or DoR of 20.8 months. The median progression-free survival or PFS was 19.4 months.

The updated data were presented in a Spotlight Poster Discussion at the 2020 San Antonio Breast Cancer Symposium (SABCS).

In the previous analysis at 11.1 months of follow-up, an ORR of 60.9 percent was seen with a median DoR of 14.8 months and median PFS of 16.4 months.

AstraZeneca and Daiichi Sankyo said that additional trials are ongoing to confirm the results seen in DESTINY-Breast01.

ENHERTU was approved in the U.S. and Japan for the treatment of HER2-positive, unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens in the metastatic setting based on the earlier results from the DESTINY-Breast01 trial.

In the U.S., ENHERTU was approved under FDA Accelerated Approval and confirmatory trials are underway.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Communications Commission or FCC has granted SpaceX Services, Inc. authorization to use its Starlink satellite internet system on vehicles in motion. SpaceX, owned by Elon Musk, is allowed to operate consumer and enterprise Ku-band Earth Stations in Motion or ESIM using frequencies allocated to the fixed satellite service. The approval would help the company to expand its services to Loud Muscle Science, LLC is recalling certain Launch Sequence products in the United States and Canada citing the presence of undeclared Tadalafil, the U.S. Food and Drug Administration said. These tainted Launch Sequence Capsule products are marketed as dietary supplements for male sexual enhancement. The U.S. Food and Drug Administration announced the intended availability of around 17 million bottles equivalent of general infant formula to be imported from New Zealand and Ireland. Under the FDA's enforcement discretion to source more infant formula to the U.S., French food company Danone SA will send 555,000 cans Aptamil Gold Plus from New Zealand.
Follow RTT